Ticker Report Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) had its target price cut by Ascendiant Capital Markets from $7.50 to $7.25 in a research report issued on Tuesday, Benzinga reports. The firm...\n more…
PR Newswire Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress Lucid Diagnostics to Host...\n more…
PR Newswire Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health PR Newswire NEW YORK, Sept. 3, 2024...\n more…
PR Newswire Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard for Early Detection of Esophageal Precancer and Cancer Lucid Diagnostics Announces Publication of Analytical...\n more…
Ticker Report Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) was the target of a significant decline in short interest in July. As of July 31st, there was short interest totalling 568,100 shares, a decline...\n more…